Login to Your Account



Clinic Roundup


Wednesday, October 19, 2011
Oxford BioMedica plc, of Oxford, UK, said the FDA cleared its investigational new drug application for a Phase I/IIa trial of UshStat, a gene-based treatment for Usher syndrome Type Ib.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription